2-chlordeoxyadenosin therapy of recurrent multifocal Langerhans cell histiocytosis in adults. Centre experience
Authors:
Z. Adam; A. Křivanová
Authors‘ workplace:
Interní hematoonkologická klinika FN Brno
Published in:
Transfuze Hematol. dnes,13, 2007, No. 2, p. 63-66.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Thirteen patients with Langerhans cell histiocytosis (LCH) have been treated in our department during the last 15 years. Tree of them with multifocal bone recidives were threated with 2-chlordeoxyadenosine as an initial therapy. These three patients are followed up for more then 24 months and they are without relapse of this disease. The 2- chlordeoxyadenosine is very efficient in multifocal bone form of LCH and has potential to reach long remission. Therefore in a case of aggressive multifocal disease we would prefer 2-chlordeoxyadenosine therapy as therapy of the first choice.
Key words:
Langerhans cell histiocytosis, 2-chlordeoxyadenosine
Sources
1. Akkari V, Donadieu J, Piguet C, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis
and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant 2003;
31(12): 1097–103.
2. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41(17): 2682–2689.
3. Bittenglova R, Pešek M, Mukenšnabl P, et al. Granulomatóza z Langerhansových buněk. Stud pneumol phtiseol 2002; 62(5): 196–202.
4. Bunanska E, Stančokova T, Dluholucky S. Histiocytóza z Langerhansových buněk. Čes-slov Pediat 1998; 53(1): 18–19.
5. Dallafior S, Pugin P, Cerny T, et al. Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide. Hautarzt 1995; 46(8): 553–60.
6. Ferreli C, Aste N, Pinna LA, et al. Langerhans cell histiocytosis in an adult. J Eur Acad Dermatol Venereol 1997; 9: 253–255.
7. Goh NS, McDonald CE, MacGregor DP, et al. Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Respirology 2003; 8(1): 91–4.
8. Gotz G, Fichter J. Langerhans’-cell histiocytosis in 58 adults. Eur J Med Res 2004; 9(11): 510–4.
9. Henter JI, Tondini C, Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004; 50 (2): 157–74.
10. Choi SW, Bangaru BS, Wu CD, et al. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and highdose cytarabine. J Pediatr Hematol Oncol 2003; 25(6): 503–6.
11. Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Amer 1998; 12: 259–268.
12. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005; 6(14): 2435–41.
13. Mottl H, Koutecký J, Ganevová M. Strategie léčby histiocytózy z Langerhansových buněk u dětí. Čes-slov Pediat 1994; 49 (2): 81.
14. Mottl H, Mracek J, Kabelka Z, et al. Histiocytóza z Langerhansových buněk u dětí. Čs Pediat 1992; 47(9): 530–533.
15. Nicholson SH, Egeler M, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Amer 1998; 12: 379–348.
16. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003; 25(7): 575–7.
17. Pacovská V, Bortlová A, Homolka J, et al. Granulomatóza z Langerhansových buněk. Trendy Med 2002; 4(4): 59–61.
18. Pardanani A, Phyliky R, Chin-Yang li, et al. 2-chlordeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003; 78: 301–306.
19. Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol 2002; 69(3): 179–84.
20. Rožánek P, Molnar V, Rešl M. Tři případy plicní granulomatózy z Langerhansových buněk. Lék zpr lék Fak Univ Karlovy Hr Kralové 1998; 43 (5/6): 127–132.
21. Saven A, Burian C. Cladribine activity in Langerhans cell histiocytosis. Blood 1999; 93: 4125–4130.
22. Saven A, Kenneth A, Foon A. 2-Chlorodeoxyadenosine induced complete remissions in Langerhans cell histiocytosis. Ann Intern Med. 1994; 121: 430–433.
23. Skácel Z, Marel M, Vraštilová P, et al. Histiocytóza z Langerhansových buněk. Přehled literatury a vlastní pozorování. Stud pneumol phtiseol 2000; 60 (4): 150–156.
24. Smilek P, Krejčová B, Čada K, et al. Histiocytóza z Langerhansových buněk, případ postižení spánkové kosti. Otorinolaryng Foniat 1994; 43(4) 263–265.
25. Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004; 43(1): 81–4.
26. Stine KC, Saylors RL, Williams LL, et al. 2-Chlordeoxyadenosine for the treatment of refractory or recurent Langerhans cell histiocytosis in pediatric patients. Medical Pediatric Oncol 1997; 29: 288–292.
27. ŠčudlaV, Roček J, Dušek B, et al. Multifokální eozinofilní granulom v dospělosti. Vnitřní Lék 2003; 33(12): 1078–1086.
28. Šímová B, Mališ J, Neuwirt J. Klinické projevy histiocytózy z Langerhansových buněk. Zdrav Nov ČR Lék Listy 2003; 52(49): 18.
29. Toušovská K, Slavík Z. Histiocytóza z Langerhansových buněk v dětském věku. Lék Zprav lék Fak Univ Karlovy Hr Králové 1997; 42(5/6): 127–132.
30. Večer J, Charvát J, Kubátová H, et al. Sekundární hemofagocytující syndrom při systémovém onemocnění. Čas Lék čes 2000; 139(12): 379–381.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2007 Issue 2
Most read in this issue
- Quantification of chimerism by real-time polymerase chain reaction.
- Autologous transplantation in 495 multiple myeloma patients – analysis from the Czech National Registry of Hematopoietic Stem Cell Transplantation
- Detection of the t(14;18) chromosomal translocation from fine-needle aspiration in follicular lymphoma and the significance of so called molecular nodal remission
- B-cell chronic lymphocytic leukemia. Part IV: Monoclonal antibody treatment options with alemtuzumab and rituximab